Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A₂, in patients with suspected sepsis and organ failureABRAHAM, Edward; NAUM, Chris; FARID, Nagy et al.Critical care medicine. 2003, Vol 31, Num 3, pp 718-728, issn 0090-3493, 11 p.Article

Cytochrome P-450 Polymorphisms and Response to ClopidogrelMEGA, Jessica L; CLOSE, Sandra L; SABATINE, Marc S et al.The New England journal of medicine. 2009, Vol 360, Num 4, pp 354-362, issn 0028-4793, 9 p.Article

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention : A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) AnalysisANTMAN, Elliott M; WIVIOTT, Stephen D; MURPHY, Sabina A et al.Journal of the American College of Cardiology. 2008, Vol 51, Num 21, pp 2028-2033, issn 0735-1097, 6 p.Article

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatmentVINCENT, Jean-Louis; BERNARD, Gordon R; WONG, Kar et al.Critical care medicine. 2005, Vol 33, Num 10, pp 2266-2277, issn 0090-3493, 12 p.Article

Severe protein C deficiency predicts early death in severe sepsisMACIAS, William L; NELSON, David R.Critical care medicine. 2004, Vol 32, Num 5, pp S223-S228, issn 0090-3493, SUPConference Paper

Dynamic evolution of coagulopathy in the first day of severe sepsis : Relationship with mortality and organ failureDHAINAUT, Jean-Francois; SHORR, Andrew F; MACIAS, William L et al.Critical care medicine. 2005, Vol 33, Num 2, pp 341-348, issn 0090-3493, 8 p.Article

Early changes in organ function predict eventual survival in severe sepsisLEVY, Mitchell M; MACIAS, William L; VINCENT, Jean-Louis et al.Critical care medicine. 2005, Vol 33, Num 10, pp 2194-2201, issn 0090-3493, 8 p.Article

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisELY, E. Wesley; LATERRE, Pierre-Francois; ANGUS, Derek C et al.Critical care medicine. 2003, Vol 31, Num 1, pp 12-19, issn 0090-3493, 8 p.Article

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical OutcomesMEGA, Jessica L; CLOSE, Sandra L; SABATINE, Marc S et al.Circulation (New York, N.Y.). 2009, Vol 119, Num 19, pp 2553-2560, issn 0009-7322, 8 p.Article

Lnterleukin-8 as a Stratification Tool for Interventional Trials Involving Pediatric Septic ShockWONG, Hector R; CVIJANOVICH, Natalie; WHEELER, Derek S et al.American journal of respiratory and critical care medicine. 2008, Vol 178, Num 3, pp 276-282, issn 1073-449X, 7 p.Article

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsisMACIAS, William L; DHAINAUT, Jean-Francois; SAU CHI BETTY YAN et al.Clinical pharmacology and therapeutics. 2002, Vol 72, Num 4, pp 391-402, issn 0009-9236, 12 p.Article

Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsisMACIAS, William L; VALLET, Benoit; BERNARD, Gordon R et al.Critical care medicine. 2004, Vol 32, Num 12, pp 2385-2391, issn 0090-3493, 7 p.Article

Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic FeverHENSLEY, Lisa E; STEVENS, Edward L; YAN, S. Betty et al.The Journal of infectious diseases. 2007, Vol 196, issn 0022-1899, S390-S399, SUP2Conference Paper

Drotrecogin alfa (activated) in children with severe sepsis : A multicentre phase III randomised controlled trial. CommentaryOPAL, Steven M; NADEL, Simon; DAZHE WANG et al.Lancet (British edition). 2007, Vol 369, Num 9564, issn 0140-6736, 803-804,836-843 [10 p.]Article

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)LEVI, Marcel; LEVY, Mitchell; SUNDIN, David P et al.American journal of respiratory and critical care medicine. 2007, Vol 176, Num 5, pp 483-490, issn 1073-449X, 8 p.Article

Drotrecogin Alfa (Activated) in Adults with Septic ShockMARCO RANIERI, V; TAYLOR THOMPSON, B; PAYEN, Didier et al.The New England journal of medicine. 2012, Vol 366, Num 22, pp 2055-2064, issn 0028-4793, 10 p.Article

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of deathABRAHAM, Edward; LATERRE, Pierre-Francois; ROSSAINT, Rolf et al.The New England journal of medicine. 2005, Vol 353, Num 13, pp 1332-1341, issn 0028-4793, 10 p.Article

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsisBARTON, Phil; KALIL, Andre C; DALTON, Heidi J et al.Pediatrics (Evanston). 2004, Vol 113, Num 1, pp 7-17, issn 0031-4005, 11 p., 1Article